

WORLD HEALTH ORGANIZATION SELECTS PROPOSED INTERNATIONAL NON-PROPRIETARY NAME FOR HMBD-002

Melbourne, Australia – 26 May 2026: Percheron Therapeutics Limited (ASX: PER) ('the Company'), an international biotechnology company focused on the development of novel therapies for oncology and rare diseases, is pleased to announce that the World Health Organization (WHO) has selected '**minperstobart**' as the proposed international nonproprietary name (INN) for HMBD-002, Percheron's investigational cancer therapy.

Key Points

- Percheron is developing HMBD-002, a novel anti-cancer therapy which targets VISTA, a key component of the immunological response to tumours.
- Prior to marketing approval, medicines generally receive an international nonproprietary name which describes the active chemical ingredient. The INN is selected by the World Health Organization, with input from the company developing the drug.
- Following an application by Percheron, WHO has selected '**minperstobart**' as the proposed INN (pINN) for HMBD-002.
- The proposed INN is expected to be definitively confirmed around May 2027. The company will continue to use the HMBD-002 designation until then, but will begin adopting the pINN for certain purposes, including clinical trial protocols and scientific publications.

"The selection of an INN is always a key waypoint as drug candidates progress towards commercialisation," commented Percheron CEO, Dr James Garner. "Since we in-licensed HMBD-002 some ten months ago, the team has been working hard to prepare the drug for the next stage of development. Applying for an INN has been one of those many activities, and we are pleased to see that specific piece of work now successfully completed. We are grateful to WHO for their review of our submission and their selection of a proposed INN designation. We look forward to seeing this confirmed in due course."

The name is expected to be published by WHO in the 136th list of Proposed International Nonproprietary Names in January 2027. After publication, a proposed INN is subject to a four-month period for comment before it is confirmed. The proposed name is consistent with other monoclonal antibody therapies of similar mechanism. Although the suffix '-mab' was traditionally used for such drug candidates, WHO has in recent years deployed a broader range of suffixes for new therapies.

While responsibility for selection of pINNs rests with WHO, Percheron was able to make recommendations and suggestions. The name minperstobart includes phonemes from both Hummingbird and Percheron, reflecting the respective roles of those companies in the genesis and development of the drug.

Background

Investigational drug candidates typically begin their development with a code number or similar designation, which is used primarily for internal administrative purposes, and which is chosen entirely by the sponsor company. HMBD-002 is an example of such a compound code number.

Typically, around the time of phase II clinical trials, an international nonproprietary name is selected. INNs are chosen by the World Health Organization or, for the United States, by the United States Adopted Names Council (USAN), based on recommendations and information provided by the sponsor company. There are strict guidelines regarding INNs, and they are not ultimately determined by the sponsor company. INNs cannot be trademarked and are not owned by the sponsor company. The INN is used to refer to any product that contains the same active ingredient, regardless of manufacturer. Minperstobart is the proposed INN for HMBD-002.

At the time of marketing authorisation, drugs receive a commercial brand name. This is selected by the sponsor company, although it must be approved by the regulatory agency for each country in which the product is marketed. The commercial brand name is trademarked and remains the property of the sponsor.

As an illustrative example, 'MK-3475' is a company code number, 'pembrolizumab' is an INN, and 'Keytruda®' is a commercial brand name.

By convention, commercial brand names are usually capitalised, whereas INNs are not, unless they begin a sentence. When both are used, the INN is typically placed in brackets after the commercial brand name. Examples include Nexium® (esomeprazole), Prozac® (fluoxetine), Viagra® (sildenafil), Panadol® (paracetamol), etc.

The Company has not yet selected a commercial brand name for HMBD-002 but expects to do so as the drug approaches commercial registration, in accordance with guidelines from FDA and other national regulatory agencies.

Next Steps

The Company will begin to deploy the INN in certain communications during CY2026, subject to confirmation by WHO, and the HMBD-002 code number will eventually be retired.

Percheron anticipates commencing a new clinical trial of HMBD-002 in 2H CY2026.

~ ENDS ~

About Percheron Therapeutics Limited

Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well-tolerated, and Percheron aims to commence further clinical trials in CY2026.

For more information, please contact info@PercheronTx.com.

*This announcement has been authorized for release to the Australian Securities Exchange
by the Board of Directors.*

For personal use only